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Summary
 
We have isolated several H-2K
 
b
 
–alloreactive cytotoxic T cell clones and analyzed their reactiv-
ity for several forms of H-2K
 
b
 
. These cytotoxic T lymphocytes (CTL) were elicited by priming
with a skin graft followed by in vitro stimulation using stimulator cells that express an H-2K
 
b
 
molecule unable to bind CD8. In contrast to most alloreactive T cells, these CTL were able to
recognize H-2K
 
b
 
 on the surface of the antigen processing defective cell lines RMA-S and T2.
Furthermore, this reactivity was not increased by the addition of an extract containing peptides
from C57BL/6 (H-2
 
b
 
) spleen cells, nor was the reactivity decreased by treating the target cells
with acid to remove peptides bound to MHC molecules. The CTL were also capable of recog-
nizing targets expressing the mutant H-2K
 
bm8
 
 molecule. These findings suggested that the
clones recognized determinants on H-2K
 
b
 
 that were independent of peptide. Further evidence
for this hypothesis was provided by experiments in which H-2K
 
b
 
 produced in 
 
Drosophila mela-
nogaster 
 
cells and immobilized on the surface of a tissue culture plate was able to stimulate hy-
bridomas derived from these alloreactive T cells. Precursor frequency analysis demonstrated
that skin graft priming, whether with skin expressing the wild-type or the mutant H-2K
 
b
 
 mol-
ecule, is a strong stimulus to elicit peptide-independent CTL. Moreover, reconstitution exper-
iments demonstrated that the peptide-independent CTL clones were capable of mediating
rapid and complete rejection of H-2–incompatible skin grafts. These findings provide evidence
that not all allorecognition is peptide dependent.
 
A
 
lloreactive T cells recognize foreign MHC molecules
and mount vigorous responses either in vivo, leading
to graft rejection, or in vitro during a mixed lymphocyte re-
action. Several models for the specificity of alloreactive T cells
have been proposed. Matzinger and Bevan (1) originally sug-
gested that these T cells recognized antigens, now known
to be peptides, bound to foreign MHC molecules. Various
modifications of this theory have focused on whether the
TCR contacts both the MHC molecule and the peptide or
either the peptide or the MHC molecule only (1). In the
latter case, although not involved in the contact with the
TCR, the bound peptide profoundly influences the con-
formation of the MHC residues comprising the epitope (2,
3). An alternate model in which alloreactive T cells recog-
nize MHC molecules in a peptide-independent fashion has
also been hypothesized (4). In this scheme, T cells recog-
nize the polymorphic differences of the foreign MHC I
molecule in a peptide-independent fashion. It is further hy-
pothesized that these peptide-independent determinants are
expressed at high densities on the surface of antigen-pre-
senting cells.
Evidence supporting the involvement of peptide in al-
loreactivity is provided by experiments in which CTL could
kill the antigen processing defective cell lines, T2 and
RMA-S, only after pulsing the targets with MHC-binding
peptides isolated from syngeneic cells (5-8). In some in-
stances, such as the anti H-2L
 
d
 
 allo clone 2C, the sequence
of the allopeptide has been determined (9). In addition,
stimulation with allogeneic APCs pulsed with a specific
peptide, elicits peptide-specific alloreactive T cells (10). Fur-
ther evidence for peptide specificity of alloreactive T cells
are experiments demonstrating that some clones require pep-
tides that are specific to certain tissues (7, 11) or species (12).
Although the above experiments have provided evi-
dence that alloreactive T cells are peptide dependent, sev-
eral observations are consistent with a peptide-independent
ligand for some alloreactive T cells. A number of reports
have described alloreactive T cells that can recognize the
TAP
 
 
 
transporter–defective cell lines, particularly if the tar-
get cells are cultured at 27
 
8
 
C (12–16). These findings are
difficult to interpret in that, although these mutant cells are
unable to efficiently transport peptides from cytosolic pro-
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teins into the endoplasmic reticulum for loading into class I
molecules, peptides from leader sequences and other pro-
teins have been identified in MHC class I molecules on the
surface of these cells (17–23). Therefore, it is possible that
alloreactive T cells that react with these mutant APCs are
specific for such peptides. In light of this explanation, the
hypothesis that some alloreactive CTL recognize either empty
MHC molecules or determinants that are unaffected by the
bound peptide is not widely accepted.
In this present report, we show that some H-2K
 
b
 
–allore-
active CTL are peptide independent in their reactivity based
on the: (
 
a
 
) ability to recognize H-2K
 
b
 
 on the antigen pre-
sentation defective cell lines T2 and RMA-S, (
 
b
 
) inability
of a peptide extract eluted from C57BL/6 spleen cells to
enhance the killing of these antigen processing defective
target cells; (
 
c
 
) failure of acid treatment of target cells to ab-
late CTL killing; (
 
d
 
) recognition of the mutant molecule
H-2K
 
bm8
 
; (
 
e
 
) reactivity with immobilized H-2K
 
b
 
 produced
in a
 
 Drosophila
 
 
 
melanogaster
 
 expression system, even after
treatment with acid to remove any bound peptide. These
peptide-independent CTL are enriched in the spleen after
priming of the mice with a skin graft. Furthermore, injec-
tion of one of these CTL clones into a T cell–depleted
mouse was sufficient to mediate rapid and complete skin
graft rejection. The identification of peptide-independent
alloreactive T cells, as well as the elucidation of an appro-
priate priming stimulus for their expansion and isolation is
in contrast to the widely accepted hypothesis that all al-
lorecognition is peptide dependent.
 
Materials and Methods
 
Mice.
 
B10.D2 and BALB/c mice were purchased from Jack-
son Laboratories (Bar Harbor, ME) and were bred to produce
(BALB/c
 
 3 
 
B10.D2) F
 
1 
 
(referred to herein as CD2F
 
1
 
) progeny.
28.1 mice are transgenic for the H-2K
 
b
 
 gene on a B10.D2 back-
ground. 29.7 mice are transgenic for the mutant (non-CD8 bind-
ing) H-2K
 
b
 
 gene on a B10.D2 background (24).
 
Target Cell Lines.
 
M12.C3 (H-2
 
d
 
) (25) or the peptide pro-
cessing defective T2 (17, 18, 21, 26, 27) and RMA/S (28-30) cells
expressing the H-2K
 
b
 
 class I molecules was generated by trans-
fecting an exon shuffled MHC class I gene encoding the H-2K
 
b
 
a
 
1 and 
 
a
 
2 domains and the H-2D
 
d
 
 
 
a
 
3 domain as previously de-
scribed (31). These cells are referred to herein as either M12.K
 
b 
 
or
T2.K
 
b
 
. T1 cells, which are the non-mutant parental cells from which
T2 were derived (17), were also transfected with H-2K
 
b
 
/D
 
d
 
 gene.
 
Generation of T Cell Clones and Hybridomas.
 
All T cell clones
described were isolated by limiting dilution from the spleens and
lymph nodes of CD2F
 
1
 
 mice that had been engrafted with trunk skin
from a 29.7 strain transgenic mouse. Lymph node and spleen cells
were harvested on day 14 after engraftment and stimulated in vi-
tro with irradiated 29.7 spleen cells. The clones were also restimu-
lated weekly with irradiated 29.7 stimulator spleen cells. Responder
and stimulator cells were co-cultured in DME/FCS(10%) con-
taining Con A–stimulated rat spleen supernatant (T cell medium).
All clones characterized in this study were confirmed, by flow mi-
crofluorimetry analysis, to be CD8
 
1
 
 
 
a/b
 
 T cells (data not shown).
The alloreactive H-2K
 
b
 
 CTL clone 4.1 was generated by limiting
dilution cloning from a primary MLR of B10.D2 stimulated with
C57BL/6 spleen cells. The ovalbumin-reactive H-2K
 
b
 
–restricted
CTL clone B3 was obtained from Dr. M. Bevan and was main-
tained as described (32). Hybridomas were developed as described
(32). In brief, 5 
 
3
 
 10
 
7
 
 clonal T cells were fused to 10
 
7 
 
BWZ.36/
CD8 
 
a
 
 cells (a derivative of the BW5147 line transfected with
a 
 
b
 
 galactosidase reporter gene behind the IL-2 promoter (33) in
1 ml of MEM/PEG-1540 (1:1 wt/vol) for 1.5 min and then slowly
diluted in 50 ml of MEM. Cells were then washed 1
 
3
 
 in HBSS
and then diluted in 100 ml of DME/FCS and aliquotted into 96-
well plates. HAT was added 24 h later and cells were refed weekly
with 1
 
3
 
 HAT-containing medium. Colonies were picked from
the 96-well plates and grown up in 24-well plates in HT-con-
taining medium before screening for reactivity. Selected hybrido-
mas were maintained in DME/FCS.
 
Assay of Cytotoxic Reactivity.
 
Cytotoxic activity was measured
in a standard 
 
51
 
Cr-release assay. Target cells were labeled with 
 
51
 
Cr
(100
 
 m
 
Ci/10
 
6
 
 cells) for 1.5 h at 37
 
8
 
C. For treatment with acid the
 
51
 
Cr-labeled target cells were suspended in a citric phosphate so-
lution (0.131 M citric acid, 0.066 M sodium phosphate, 1% BSA)
at pH 3.0 (34). M12 cells were incubated in acid for 15 min, and
T2 cells for 8 min, at room temperature. They were recovered by
centrifugation and resuspended in DME/FCS. After this treat-
ment, the viability of the cells was generally around 75% as as-
sessed by trypan blue exclusion. Labeled target cells (5,000 per well),
were added to each well of a V-bottom microtiter plate and incu-
bated with effectors at the indicated E/T ratios at 37
 
8
 
C for 4–6 h.
Percent specific release was calculated using the following for-
mula: [(E 
 
2 
 
S/(M 
 
2 
 
S)] 
 
3
 
 100, where 
 
E
 
 is the average experi-
mental release of duplicate samples, 
 
S
 
 is the average spontaneous
release of triplicate samples and 
 
M
 
 is the average maximum re-
lease of triplicate samples. Spontaneous release was measured in
the absence of effector cells, while maximum release was mea-
sured in the presence of 1% NP-40 instead of effector cells.
 
Preparation of Peptide Extract.
 
Cell suspensions prepared from
the spleens of C57BL/6 mice were washed extensively and then
homogenized in 0.1% TFA. The suspension was adjusted to pH
2.0 with HCl, sonicated 20 
 
3
 
 1 s and then incubated at 4
 
8
 
C for
60 min. Cellular debris was removed by centrifugation at 2,000 
 
g
 
for 20 min and the supernatant was then passed through a Centri-
con 10 membrane, lyophilized, and resuspended in sterile distilled
water.
 
Production and Purification of Soluble H-2K
 
b
 
.
 
Soluble H-2K
 
b
 
 was
prepared as described (35). In brief, a truncated form of H-2K
 
b
 
, en-
coding a six-histidine tail after amino acid 273 of the mature pro-
tein was inserted into the 
 
Drosophila
 
 expression vector pRMHa-3.
A full-length cDNA encoding mouse 
 
b
 
2 microglobulin was like-
wise introduced into pRMHa-3. These constructs were co-trans-
fected together with pHSneo into 
 
Drosophila
 
 
 
melanogaster 
 
SC2
cells and cells were selected in geneticin-containing medium. Pro-
tein expression was induced by the addition of CuSO
 
4
 
 and the
cell supernatant was harvested after 3 d. The concentrated cell su-
pernatant was purified on a Ni-NTP column followed by ion ex-
change chromatography.
 
Assay for Stimulation of Hybridomas by Immobilized H-2K
 
b
 
.
 
Im-
mulon 3 plates were coated with 50 
 
m
 
l/well of soluble H-2K
 
b
 
 at a
concentration of 5
 
 m
 
g/ml for 2 h at 37˚C and then washed twice
with PBS. Hybridoma T cells were added to the coated plate at
a concentration of 10
 
5
 
/well
 
 
 
and incubated overnight at 37˚C.
 
b
 
-galactosidase activity was assayed using 5 nM ONPG (
 
o
 
-nitrophe-
nol-
 
b
 
-galatopyranoside) as the colorimetric reagent (33). Absorp-
tion was read in a ELISA plate reader at 405 nm 4 h after addition
of the developing reagent. The immobilized H-2K
 
b
 
 was acid
treated to remove any bound peptide by adding 100
 
 m
 
l of 100
 
m
 
M sodium acetate/acetic acid buffer (pH 3.0) to H-2K
 
b
 
–coated 
1025
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wells for 15 min at 4˚C, followed by 3 washes with PBS. For ex-
periments involving pulsing with the SIINFEKL peptide, H-2K
 
b
 
–
coated wells were incubated with (30
 
 m
 
M) SIINFEKL in PBS for
3 h at 37˚C and then washed 3
 
3
 
 with PBS.
 
Precursor Frequency Analysis.
 
Spleen cells from CD2F
 
1
 
 mice were
cultured at titrated concentrations, each concentration repeated
24 times, in V-bottom 96 well plates. The CD2F
 
1
 
 mice were ei-
ther unprimed or primed with an H-2K
 
b
 
 incompatible skin graft.
The engrafted mice were killed two weeks after engraftment, a
time period sufficient in all cases for complete graft rejection.
CD2F
 
1
 
 cells were stimulated with 10
 
6 
 
irradiated spleen cells per
well and, in addition, 10
 
5
 
 irradiated spleen cells from the re-
sponder. All cultures included 10% rat spleen cell con A superna-
tant as a source of IL-2. After 1 wk of stimulation, the cultures
were assayed for cytolysis of
 
 51
 
Cr-labeled target cells during a 4-h
incubation. The precursor frequency was calculated by determin-
ing the cell concentration at which 37% of the wells were nega-
tive, using a graph of the log percentage of negative wells on the
ordinate and the responder cell concentration on the abscissa. De-
termination of the cut off for positive wells was made by cultur-
ing 24 wells of responder cells at the highest concentration used
in a particular assay, with no stimulators, and then calculating the
average CTL value readout plus three standard deviations.
Transfer of CTL into T Cell–depleted Mice. CD2F1  mice were
thymectomized at 5 wk of age and then T cell depleted with a se-
ries of four intraperitoneal injections of antibody to CD4 (GK1.5)
and CD8 (YTS.169.4 ) on days 29, 27, 24 and 0. Fluorescence
microfluorimetric analysis of lymph node cells confirmed T cell
depletion (data not shown). CD2F1 mice were then engrafted
with trunk skin from 29.7 donors. 60 d after engraftment, mice
were injected intravenously with 107 T cells and the fate of the
grafts monitored by daily observation. Rejection was defined as
complete graft ablation.
Results
Anti–H-2Kb–alloreactive CTL Clones Can Kill T2 Cells
Expressing H-2Kb. Allo H-2Kb reactive CTL clones were
isolated from the H-2d mice, (BALB/c 3 B10.D2)F1, after
stimulation with cells from strain 29.7. Strain 29.7 are
B10.D2 (H-2d) mice transgenic for an H-2Kb gene that
carries a substitution in the a3 domain (glutamic acid to ly-
sine at residue 227) which prevents association with CD8.
The F1 mice were primed in vivo with a skin graft and, af-
ter rejection of the graft, CTL clones were isolated from
the spleen by in vitro restimulation. A total of 88 clones
were isolated. Of these 88 clones, 80 were able to kill an
H-2Kb transfectant of the antigen processing–defective cell
line T2, with a specific lysis of 22% or greater (Fig. 1).
From this panel of CTL clones, 6 were selected for further
analysis.
The initial indication that killing by these six clones was
independent of peptide was their ability to lyse T2 cells trans-
fected with the H-2Kb gene (Fig. 2). The killing was H-2Kb
specific because there was no reactivity for non-transfected
T2 cells (Fig. 2) nor T2 cells transfected with H-2Ld (data
not shown). All six clones were also assayed for their ability
to kill M12.C3 (H-2d) as well as L cells (H-2k), and in all
cases lysis was only observed with transfected target cells that
express H-2Kb (data not shown). Further demonstrating
peptide independence, the addition of an extract contain-
ing peptides recovered from C57BL/6 (H-2b) spleen cells
did not enhance the killing of T2.Kb by these 6 clones (Fig. 2).
This extract was capable of sensitizing T2.Kb cells for lysis
by the H-2Kb specific, peptide-dependent alloreactive T cell
clone 4.1 (Fig. 2). We also compared the reactivity of our
six peptide-independent clones (three of which are shown
in Fig. 3) for wild-type T1.Kb and mutant T2.Kb cells. Also
Figure 1. Cytotoxic reactivity of CTL clones for T2.Kb targets. Each
symbol represents one of the original 88 clones isolated from one of two
mice primed in vivo with a skin graft from a 29.7 mouse and restimulated
with 29.7 spleen cells. The E/T ratio was 20:1. 80 of the 88 clones kills
T2.Kb targets with a specific lysis of 22% or greater.
Figure 2. Cytotoxic reactivity of seven H-2Kb–specific alloreactive
CTL clones for T2.Kb (open squares), T2.Kb pulsed with peptide extract
derived from C57BL/6 spleen cells (filled circles), and T2 (filled diamonds)
cells. In the top panel is shown the peptide-dependent CTL clone 4.1,
which can kill T2.Kb cells only in the presence of the peptide extract from
C57BL/6 spleen cells. In contrast, killing of T2.Kb cells by the other six
clones (20, 34, 39, 40, 41, and 59) does not require, nor is it enhanced by,
the addition of the peptide containing extract.1026 Peptide-independent Recognition by Alloreactive CTL
shown is their reactivity for T2.Ld cells. The peptide-inde-
pendent CTL were able to lyse both Kb transfected targets
to a similar degree, whereas the 4.1 clone killed T1.Kb but
not T2.Kb cells. Furthermore, treatment of T2.Kb cells with
acid to remove peptides bound to MHC molecules did not
abolish the reactivity of the CTL for T2.Kb (Fig. 4). To
demonstrate the effectiveness of acid stripping, we showed
(Fig. 4) that it abolishes killing, by the peptide-dependent
clone 4.1, of T2.Kb targets pulsed with C57BL/6 spleen cell
extract. Although the reactivity of the peptide-independent
clones for T2.Kb was somewhat decreased after acid treat-
ment (Fig. 2 versus Fig. 4), this is probably a consequence
of target cell damage inflicted by the acid. Such treatment
kills between 30 and 50% of the targets, and the E/T ratio
reflects targets that are still viable after acid stripping. This
experiment was also performed using CTL clones 20, 40,
and 59, along with the peptide-dependent control, 4.1, on
M12.Kb target cells. As shown in Fig. 5, the acid treatment
completely abolished the reactivity of 4.1 for M12.Kb cells,
but only partially inhibited reactivity of clones 20 and 40
for M12.Kb. The lytic capacity of clone 59 for M12.Kb was
not affected by the acid treatment. Lysis of the M12 targets
by these CTL demonstrates specificity for H-2Kb as M12.Kb,
but not M12.C3 cells, were killed.
The Anti–H-2Kb–alloreactive CTL Can Kill RMA-S Cells.
Although the T2 cell line does not express serologically de-
tectable levels of HLA molecules on its surface, transfection
of mouse class I genes, such as H-2Kb, leads to very high
levels of serologically detectable product on the surface of
the T2 cells. We examined whether our CTL clones would
recognize H-2Kb on the surface of the H-2b cell line RMA-S,
which also is defective in antigen processing and, when
cultured at 378C, does not express any serologically detect-
able H-2Kb. Despite this low level of expression of H-2Kb
on RMA/S, they were readily killed by the CTL clones
(Fig. 6). The ability of the CTL clones to recognize H-2Kb
on the surface of T2 and RMA-S cells also suggests that
these CTL do not require the presence of a particular pep-
tide derived from a particular cytosolic protein.
Peptides Present in Fetal Calf Serum Do Not Contribute to the
Determinant(s) Recognized by CTL. A possible interpretation
of the above observations is that there are peptides in the
FCS in the culture media that are capable of binding to H-2Kb
on the surface of T2.Kb and RMA-S cells and that the
CTL, which were isolated in vitro, recognized a determi-
nant comprised of this peptide. This possibility was exam-
ined by culturing the target cells in serum-free media for 10 d
before use in a cytotoxicity assay which was also performed
in serum-free conditions. As shown in Fig. 7, target cells
cultured in serum-free media were readily lysed by all six of
the CTL clones tested, demonstrating that recognition by
these T cells do not require FCS-derived peptides.
The Anti H-2Kb CTL Clones Are also Capable of Killing
T2 Cells Expressing H-2Kbm8. The H-2Kbm8 molecule has
mutations at residues 22, 23, 24, and 30, which lead to dif-
ferences from wild-type H-2Kb in the peptides bound and
presented (36, 37), as well as changes in the conformation
of bound peptides common to both H-2Kb and H-2Kbm8
Figure 3. Cytotoxic reactivity of three H-2Kb–specific alloreactive CTL
clones (39, 40, and 59), as well as the peptide-dependent H-2Kb–specific
alloreactive clone 4.1, for T2.Kb (filled squares), T1.Kb (open circles) and
T2.Ld (filled diamonds) cells. Clones 20, 34, and 41 also show similar reac-
tivity for these targets (data not shown).
Figure 4. Cytotoxic reactiv-
ity of six H-2Kb–specific allore-
active CTL clones for T2.Kb cells
after acid stripping. The clones are
denoted by the following symbols:
(filled squares) 20; (filled triangles)
34; (filled circles) 39; (open squares)
40; (open triangles) 41; (open circles)
59. The panel on the right repre-
sents the cytotoxic reactivity of the
H-2Kb–specific alloreactive clone
4.1 for T2.Kb (open squares), T2.Kb
treated with acid (closed squares),
T2.Kb pulsed with C57BL/6
spleen cell–derived peptide extract
(open circles), and T2.Kb pulsed
with peptide extract followed by
acid treatment (closed circles).1027 Smith et al.
(38). The ability of all of our anti H-2Kb CTL clones to kill
T2 cells expressing H-2Kbm8 molecules (Fig. 8) is consistent
with these T cells recognizing determinants that are not de-
pendent upon particular peptides.
Recognition of H-2Kb Produced in a Drosophila Expression
System, by Alloreactive T Cells. An expression system using
Drosophila melanogaster cell lines has been used to produce
quantities of soluble H-2Kb molecule (39). The H-2Kb iso-
lated from this system are mostly devoid of peptides (39,
40), although some of the H-2Kb molecules contain a pep-
tide derived from the yeast extract used as a supplement in
the culture media. This yeast-derived peptide has low affin-
ity for H-2Kb and does not possess the motif found in pep-
tides which bind to H-2Kb with high affinity. To assay the
ability of the anti–H-2Kb alloreactive T cells to recognize
the H-2Kb produced by Drosophila melanogaster cells, T cell
hybridomas were produced. The fusion partner used was a
derivative of the BW5147 line transfected with a b-galac-
tosidase reporter gene inserted behind the IL-2 promoter
(33). Upon engagement of the TCR, hybridomas prepared
using this fusion partner produce b-galactosidase which can
be detected by a colormatic assay. Hybridomas were pre-
pared from clones 34 and 59, and both reacted readily with
T2 cells transfected with H-2Kb (data for hybridoma 34.9,
derived from clone no. 34, shown in Fig. 9 A) and not
with T2 cells transfected with the H-2Ld molecule (data
not shown).
Both of the hybridomas reacted strongly with H-2Kb
immobilized on the surface of an ELISA plate (data for hy-
bridoma 34.9 shown in Fig 9 B). Therefore, the T cells
were able to recognize H-2Kb produced by the Drosophila
expression system. To confirm that this reactivity was not
dependent upon a peptide associated with the H-2Kb pro-
duced by the Drosophila cells, the immobilized H-2Kb was
treated with sodium acetate/acetic acid buffer (pH 3.0) to
remove any bound peptide, before addition of the hybri-
doma cells. Serological analysis demonstrated that the acid
treatment did not remove a significant amount of the
bound H-2Kb (data not shown). The reactivity of the al-
loreactive hybridomas was unaffected by the acid treatment
of the immobilized H-2Kb (Fig. 9 b). The efficiency of the
acid treatment was demonstrated by its ability to com-
pletely remove the ovalbumin-derived peptide SIINFEKL,
which binds to H-2Kb with high affinity. The reactivity of
a hybridoma derived from the H-2Kb-SIINFEKL–reactive
clone, B3 (B3.53), for peptide pulsed H-2Kb was abolished
after acid treatment (Fig. 10). Overall, this data demon-
strates that the anti H-2Kb T cell hybridomas recognize the
H-2Kb produced by Drosophila cells in a peptide-indepen-
dent manner.
Peptide-independent Alloreactive CTL Are Enriched after a
Skin Graft. The precursor frequency of CTL reactive
Figure 5. Cytotoxic reactiv-
ity of three H-2Kb–specific al-
loreactive CTL clones, as well as
the peptide-dependent H-2Kb–
specific alloreactive clone 4.1, for
M12.C3 (H-2d) M12.Kb, and
M12.Kb cells after acid stripping.
The clones are denoted by the
following symbols: (filled squares)
20; (filled triangles) 40; (filled cir-
cles) 59; (open diamonds) 41.
Figure 6. Cytotoxic reactivity of the six H-2Kb–specific alloreactive
CTL clones for RMA-S target cells. The clones are denoted by the fol-
lowing symbols: (filled squares) 20; (filled triangles) 34; (filled circles) 39; (open
squares) 40; (open triangles) 41; (open circles) 59.
Figure 7. Comparative cyto-
toxic reactivity of the six H-2Kb–
specific alloreactive CTL clones
against T2.Kb targets with (filled
bars) and without (open bars)
FCS. In assays with FCS, DME/
FCS was used as the growth me-
dium and the CTL assay me-
dium. In those without FCS, the
targets were grown in OPTI-
MEM for 10 d before the CTL
assay, and OPTI-MEM was also
used as the CTL assay medium.
The E/T ratio in all determina-
tions was 10:1.1028 Peptide-independent Recognition by Alloreactive CTL
with T2.Kb and M12.Kb cells was determined in naive mice
and mice primed in vivo with an H-2Kb–incompatible skin
graft. The skin graft donors were transgenic mice express-
ing either the wild-type or the mutant (CD8 non-binding)
H-2Kb gene. The frequency of H-2Kb–alloreactive T cells
that reacted with either M12.Kb or T2.Kb cells after pri-
mary in vitro stimulation with the wild-type H-2Kb mole-
cule was greater than the frequency observed after stimula-
tion with the mutant H-2Kb molecule (Table 1). For either
in vitro stimulus, the pCTL frequency of T cells reactive to
M12.Kb targets was greater than the frequency of T cells
reactive to T2.Kb targets. In mice grafted with either mu-
tant or wild-type H-2Kb incompatible skin, the pCTL fre-
quencies of T cells reactive with T2.Kb cells were compara-
ble to that of CTL reacting with M12.Kb (Table 1). Thus,
skin grafting enriches for T2.Kb-reactive CTL.
To determine whether the dramatic increase in peptide-
independent CTL after skin grafting was confined to lysis
of T2.Kb targets, pCTL assays were also performed using
RMA-S targets. The frequency of pCTL reactive with
RMA-S cells in naive or skin grafted mice was similar to
the pCTL frequency reactive to T2.Kb targets. To confirm
that the reactivity observed is not a consequence of the rec-
ognition of the limited repertoire of peptides expressed by
H-2Kb on T2 and RMA-S cells, the pCTL frequency for
acid treated T2.Kb targets was determined, and found to be
comparable to the frequency of pCTL reacting with un-
treated T2.Kb targets. To determine whether these CTL
were more highly reactive with H-2Kb plus peptide than
with the peptide-deficient H-2Kb molecules presented by
T2.Kb, we compared the pCTL frequency of T cells recog-
nizing T2.Kb cells in the presence or absence of an extract
containing MHC-bound peptides from C57BL/6 spleen
cells. The pCTL frequencies were similar for the reactivity
Figure 8. Cytotoxic reactivity of the six H-2Kb–specific alloreactive
CTL clones for T2.Kbm8 target cells. The clones are denoted by the fol-
lowing symbols:  (filled squares) 20; (filled triangles) 34; (filled circles) 39; (open
squares) 40; (open triangles) 41; (open circles) 59.
Figure 9. (A) Reactivity of alloreactive anti H-2Kb hybridoma 34.9
with non-transfected T2 and T2 cells transfected with H-2Kb. (B) Reac-
tivity of hybridoma 34.9 to immobilized soluble H-2Kb treated with ei-
ther PBS at pH 7.4 (middle) or 100 mM sodium acetate/acetic acid buffer
at pH 3.0 (right). In both panels, activation was determined by a colori-
metric assay with ONPG as the b-galactosidase substrate. Absorbance was
read at 405 nM.
Figure 10. Reactivity of the H-2Kb ovalbumin (SIINFEKL)-specific
hybridoma B3.53 to immobilized H-2Kb pulsed with the SIINFEKL pep-
tide. Activation was determined by a colorimetric assay with ONPG as
the b-galactosidase substrate. Absorbance was read at 405 nM. B3.53 is
stimulated only by H-2Kb in the presence of SIINFEKL peptide, and acid
treatment of this complex removes the peptide and abrogates the ability of
the complex to stimulate the hybridoma.1029 Smith et al.
with T2.Kb in the presence or absence of the extract. Simi-
larly, the pCTL frequency for reactivity with T1.Kb, the
counterpart of T2.Kb that processes peptide normally, was
similar to the pCTL frequency for T2.Kb. Thus, skin graft
priming enriches for peptide-independent alloreactive CTL.
A Peptide-independent Anti–H-2Kb–allospecific T Cell Clone
Is Capable of Mediating Skin Graft Rejection. The ability of
one of the anti H-2Kb CTL clones, no. 59, to mediate re-
jection of an H-2Kb incompatible skin graft was examined
in thymectomized, T cell–depleted mice. Neonatally thymec-
tomized CD2F1 mice were depleted of T cells by multiple
injections of antibodies to CD4 and CD8. These mice
were then grafted with skin from 29.7 transgenic mice. 60 d
after engraftment, 107 clone no. 59 cells were injected in-
travenously. In 8 out of 8 mice, the grafts were totally re-
jected within 16 d (range 10–16 d) after injection of the
CTL clone. In contrast, mice not injected with clone no.
59 retained the H-2Kb–incompatible graft without any sign
of rejection at 120 d after grafting. Thus, clone no. 59 is ca-
pable of mediating graft rejection.
Discussion
The reactivity of the majority of alloreactive T cells is
considered to be peptide specific. This conclusion is based
on several studies in which most of the alloreactive T cells
characterized did not recognize class I molecules on T2 or
RMA-S cells without the addition of peptide extracts pre-
pared from normal cells expressing the relevant MHC class
I (5–8). When lysis of peptide processing–defective targets
was observed, it was usually enhanced by additions of ex-
ogenous peptide extracts from wild-type cells, suggesting
that the determinant recognized was actually peptide de-
pendent (6, 13, 15). In some instances, including the anti–
H-2Ld allo clone 2C (9), as well as clones alloreactive with
Qa-1 (41), H-2Kb (42), and HLA-A3 (43) the sequence of
the allopeptide has been determined. In addition, stimula-
tion with allogeneic APCs pulsed with a specific peptide
can elicit peptide-specific alloreactive T cells (10). Further
evidence for peptide specificity of alloreactive T cells was
provided by experiments that demonstrated that some T cell
clones require peptides that are specific for either certain
tissues (7, 11) or species (12). In contrast, the data presented
herein demonstrates that some anti–H-2Kb alloreactive CTL
clones are able to recognize determinants that do not re-
quire a particular peptide. We established this by several
criteria: (a) the ability to recognize H-2Kb on the antigen
presentation–defective cell lines T2 and RMA-S, (b) the
inability of a peptide extract eluted from C57BL/6 spleen cells
to enhance the killing of these antigen processing–defective
target cells; (c) the failure of acid treatment of target cells to
reduce CTL killing; (d) recognition of the mutant molecule
H-2Kbm8; (e) recognition of plate-bound H-2Kb even after
treatment with acid to remove any bound peptide. The
identification of these cells confirms that, in addition to
peptide determined ligands, the polymorphic differences of
the MHC molecules themselves can define allo determi-
nants for T cell recognition.
Although it has been established that many alloreactive
T cells are peptide specific, such evidence does not exclude
the possibility of peptide-independent allorecognition by
some T cells. Peptide-independent allorecognition was first
proposed by Bevan (4) who suggested that it was influ-
enced by high determinant density on the target cell. Ac-
cording to this model MHC determinants that are not in-
fluenced by peptide are present on most of the target
molecules thereby enabling a high density ligand to com-
pensate for the low affinity of the TCR for the alloanti-
genic molecule (44, 45). Indeed, the neonatal T cell reper-
toire exhibits peptide promiscuity in T cell recognition
(46) suggesting that these T cells recognize the MHC mol-
ecule directly. Moreover, there are several reports charac-
terizing alloreactive CTL that are not peptide specific (12,
13, 15, 16, 47). In addition it has been shown that some al-
loreactive gd T cells are able to recognize determinants un-
affected by mutations in the MHC molecule that alter pep-
tide presentation of self-MHC–restricted ab T cells (48).
Perhaps the most definitive evidence for peptide-inde-
pendent allorecognition is provided by a CTL line that
Table 1. Frequency of Anti–H-2Kb–alloreactive CD2F1 Spleen 
Cells after a 7-d MLR with Stimulator Spleen Cells Expressing Either 
Wild-Type H-2Kb or Mutant H-2Kb That Does Not Engage CD8
Graft* Stimulator‡ Target pCTL (1/...)
None Kb.wt M12.Kb 17,634 6 7,436
None Kb.m M12.Kb 210,723 6 74,515
None Kb.wt T2.Kb 64,199 6 9,151
None Kb.m T2.Kb 462,429 6 26,640
Kb.wt Kb.wt M12.Kb 12,179 6 6,663
Kb.m Kb.m M12.Kb 15,690 6 4,638
Kb.wt Kb.wt T2.Kb 7,357 6 4,241
Kb.m Kb.m T2.Kb 10,637 6 7,042
None Kb.m RMA/S 391,408
Kb.m Kb.m RMA/S 14,672
None Kb.m T2.Kb acid treated 92,557
Kb.wt Kb.wt T2.Kb acid treated 11,376
None Kb.m T2.Kb acid treated 352,718
Kb.m Kb.m T2.Kb acid treated 3,018
Kb.m Kb.m T2.Kb 1
C57BL/6 extract
7,333 6 4,552
None Kb.wt T1.Kb 11,637
Kb.wt Kb.wt T1.Kb 3,398
Kb.m Kb.m T1.Kb 4,201
*CD2F1 mice were grafted with 28.1 (transgenic for wild-type H-2Kb,
denoted Kb.wt) or 29.7 (transgenic for mutant H-2Kb that does not en-
gage CD8, denoted Kb.m) trunk skin. Spleen cells were harvested 14 d
after skin grafting. At this time, the grafts were completely rejected.
‡MLR stimulators were either 28.1 (Kb.wt) or 29.7 (Kb.m) spleen cells.
The MLR represents either a primary anti–H-2Kb in vitro stimulation
of cells from naive mice, or a secondary in vitro stimulation of spleen
cells from mice that received an H-2Kb (wild type per mutant)–incom-
patible skin graft.1030 Peptide-independent Recognition by Alloreactive CTL
proliferated upon incubation with plate-bound HLA-A2
that had been denatured, purified, and renatured in the ab-
sence of peptide (16). The authors did not, however, estab-
lish the validity of the system by incorporating a peptide-
dependent control, nor did they address the possibility that
a peptide in the FCS bound to the isolated class I molecule
and contributed to the allodeterminant. Several other re-
ports have also described CTL clones that may recognize
peptide-independent ligands. For example, alloreactive T cell
clones which can recognize H-2Kb on RMA-S (13, 15), or
either HLA-A2 (14, 16) or transfected murine class I mole-
cules on T2 (12) cells have been described. Some of these
alloreactive CTL lyse RMA/S to the same extent as they
kill RMA, the wild-type counterpart of RMA/S (13). In
such studies the possibility that class I molecules on RMA/S
and T2 can present peptides for which such CTL cells are
specific was not directly addressed. Attempts by others to
deal with this issue have involved extracting peptides from
RMA/S cells (15) in order to isolate particular fractions to
add back to RMA/S cells for higher density presentation.
Although lysis by some alloreactive clones was enhanced by
pulsing RMA/S targets with a particular peptide fraction,
the recognition by other clones appeared to be truly pep-
tide independent. The interpretation of all these observa-
tions, then, is complicated by evidence that the T2 and
RMA-S cell lines can present a repertoire of peptides in-
cluding those derived from either signal sequences in the
endoplasmic reticulum (17, 18), from minigenes that incor-
porate sequences for targeting fusion proteins to the endo-
plasmic reticulum (19) or from influenza (21), sendai (20),
murine leukemia (22), and vesicular stomatitis (21, 23) vi-
ruses. Overall, such observations demonstrate that the in-
ability of RMA-S and T2 cells to present peptides in asso-
ciation with class I molecules is not absolute. Therefore,
killing these targets by alloreactive CTL is insufficient evi-
dence to conclude that such CTL recognize peptide-inde-
pendent epitopes. For such reasons the existence of pep-
tide-independent alloreactive T cells is controversial, and for
the most part, widely overlooked.
Among the alloreactive CTL that are able to kill RMA/S
or T2 cells, there are three discernible phenotypes distin-
guished by alterations in their reactivity resulting from the
addition of exogenous peptides capable of binding to the
target MHC class I molecule (6, 15). The reactivity of
many alloreactive CTL that are able to kill RMA/S or T2
is enhanced by the addition of peptides eluted from wild-
type cells expressing the target molecule, suggesting that
such CTL are peptide dependent. A second phenotype is
manifest by CTL that can kill RMA/S or T2 cells in the
absence of added peptide, but if the targets are pulsed with
high concentrations of a single synthetic peptide able to
bind the molecule for which they are specific, the reactivity
is decreased (13) or abolished (Smith, P.A., and T.A. Potter,
unpublished observations). Such T cells are considered to
recognize either empty class I molecules, class I molecules
containing one of several peptides that result in a particular
conformation, or class I molecules containing a specific
peptide that is displaced by the addition of the exogenous
synthetic peptide. A third phenotype is comprised of CTL
that lyse RMA/S even in the presence of high concentra-
tions of added synthetic peptide (13). Such CTL could be
reacting either with a peptide that is not displaced by the
added peptide or, alternatively, these CTL may recognize a
determinant that is unaffected by the presence or absence
of a particular peptide. We have determined (data not
shown), that pulsing T2.Kb target cells with high concen-
trations of synthetic peptides such as SIINFEKL, did not
displace peptides already bound to H-2Kb. For example,
the peptide-dependent 4.1 CTL clone lysed T2Kb cells pulsed
with peptide extracted from C57BL/6 spleen cells. This re-
activity was ablated by treatment of the target cells with
acid to remove peptides bound to MHC molecules, but it
was not diminished by the addition of micromolar amounts
of SIINFEKL. Thus, pulsing with high concentrations of
synthetic peptide, unlike acid treatment, does not necessar-
ily displace all MHC-bound peptides.
The killing of RMA/S or T2.Kb cells by the CTL we
describe here was not enhanced by the addition of peptide
extract derived from C57BL/6 spleen cells, nor was it di-
minished by acid treatment of the target cells. To further
characterize whether peptides were required for the deter-
minant recognized by our CTL, we examined the reactivity
with the H-2Kbm8 molecule which carries several substitu-
tions that lead to differences in allorecognition and peptide
binding compared to wild-type H-2Kb (37). In addition to
binding their own unique set of peptides, the H-2Kbm8 and
H-2Kb molecules also bind some common peptides, al-
though these overlapping peptides are bound in a different
conformation by the two molecules (49). The observation
that our alloreactive CTL are able to recognize both H-2Kb
and H-2Kbm8 is consistent with a peptide independence of
the epitope recognized. The CTL clones that we generated
were isolated in vitro in the presence of fetal bovine serum,
thus it was a formal possibility that the serum contained a
peptide which was capable of binding to H-2Kb on the cell
surface and thereby eliciting a response specific for this
complex. This possibility is particularly relevant when as-
saying on transfectants of T2 cells, because they express
transfected murine MHC class I molecules which bind ex-
ogenous peptide very efficiently. Culture of the transfected
T2 cells in serum-free conditions did not affect killing by
the CTL, indicating that FCS derived peptides did not
contribute to the epitope(s) recognized. Finally, we derived
hybridomas from two of our CTL clones, so that we could
analyze the response to H-2Kb produced in Drosophila mela-
nogaster cells which do not possess the ability to load pep-
tide (39, 40). The hybridomas reacted strongly to the im-
mobilized H-2Kb even after the molecule had been treated
with acid to remove any bound peptide. This observation
provides very strong evidence that the recognition of H-2Kb
by these T cells is peptide independent.
After skin graft priming, there was an increase in the
pCTL frequency of CTL reacting with both RMA/S and
T2.Kb. To confirm that this reactivity does not represent
recognition of the limited repertoire of peptides expressed
in association with H-2Kb on these target cells, we assayed1031 Smith et al.
the ability of these CTL to kill acid-treated target cells. The
pCTL frequency of T cells recognizing T2.Kb was unaf-
fected either by treatment of the target cells with acid to re-
move MHC-bound peptides or by addition of an extract
containing MHC-bound peptides from cells which express
H-2Kb. Furthermore, the frequency of pCTL reacting with
T1.Kb, the counterpart of T2.Kb which processes peptide
normally, was essentially the same as the pCTL frequency
of cells reacting with T2.Kb.
In our efforts to isolate peptide-independent alloreactive
cells, we initially used skin graft priming followed by an
MLR with stimulator cells expressing a mutant form of H-2Kb
that does not engage CD8. Our rationale was that, by se-
lecting for T cells that do not require CD8 engagement for
activation, we would isolate either T cells that recognize
H-2Kb in association with a particular peptide with very high
affinity or, alternatively, recognize a high-density ligand with
a lower affinity. The latter possibility is based on previous
reports (50–52) which demonstrated a correlation between
CD8 dependence and ligand density. Thus, by removing
the ability of the TCR and the CD8 molecule to simulta-
neously engage H-2Kb, T cells that can recognize high-
density ligands may be selected. The examples of high-den-
sity allo determinants would include those that do not require
a particular peptide, either (a) epitopes common to all H-2Kb
complexes, (b) epitopes dependent on highly abundant pep-
tides, (c) epitopes shared by H-2Kb associated with several
different peptides, and (d) empty H-2Kb. As our precursor
frequency data shows, abrogation of CD8 engagement does
decrease the reactivity to H-2Kb–expressing targets in a pri-
mary MLR by about an order of magnitude, suggesting
that, in the absence of CD8 engagement, the frequency of
H-2Kb–reactive CTLs in unprimed mice is low. The fre-
quency of pCTL recognizing the mutant H-2Kb molecule is
increased dramatically after priming in vivo with a skin
graft. Subsequent experiments also revealed that the fre-
quency of pCTL reactive with T2.Kb alloreactive cells is
comparable whether or not the H-2Kb expressed by the
skin graft and MLR stimulators can engage CD8. Thus,
skin grafting is very efficient for enriching and selecting for
peptide-independent alloreactive T cells. We have recently
isolated an additional 9 CTL lines from mice primed with
and restimulated in vitro with wild-type H-2Kb which be-
have similarly to the clones described in this paper. All of
these nine lines are H-2Kb specific, lyse T2.Kb and T1.Kb
cells with the same efficiency, and their lysis of T2.Kb cells
is not enhanced by the addition of the C57BL/6 spleen cell
extract (data not shown).
Skin grafting is a very potent allo-stimulus, and may be
very efficient in selecting T cells that recognize a high-den-
sity ligand such as peptide-independent epitopes. Although
evidence for peptide-independent alloreactive T cells has
previously been reported (12–15), they are generally found
at a low frequency relative to peptide-dependent T cells.
This may be related to the methodology used for their iso-
lation, particularly in terms of in vivo priming. Many of the
characterized alloreactive T cells are obtained from a pri-
mary in vitro stimulation or after interperitoneal injections
of spleen or tumor cells expressing allo determinants. These
conditions may not adequately encompass all of the allore-
sponse. This is particularly apparent in our studies which
demonstrated the enhanced selection of peptide-indepen-
dent T cells by priming with a skin graft.  Skin contains a
large number of Langerhans cells that, upon transplanta-
tion, migrate to local lymph nodes of the recipient and ac-
tivate naive T cells (53, 54). Moreover, a correlation be-
tween Langerhans cell density and the rapidity of skin graft
rejection has been established (54). Perhaps, then, the fine
specificity of alloreactive T cells isolated after potent stimu-
lation by Langerhans cells includes T cells that recognize a
ligand present at a high density, namely the H-2Kb mole-
cule regardless of peptide occupancy.
The observation that transfer of a peptide-independent
CTL clone was sufficient to confer the ability to reject an
H-2Kb incompatible skin graft, suggests that further studies
of the fine specificity of alloreactive T cells elicited during
the rejection of different tissues are required. This is partic-
ularly applicable for prospective clinical treatments to cir-
cumvent transplantation rejection. For example, based upon
studies showing peptide-restricted allo-responses of CD4
cells to MHC class II molecules (55, 56), it has been sug-
gested that the prevention of allograft rejection might be
accomplished by induction of tolerance to specific peptide
determinants (56). Since our peptide-independent clones
were primed by a graft in which the only disparity was the
class I H-2Kb molecule, the success of this suggested ap-
proach in preventing rejection of a MHC class I disparate
graft would depend on whether the stimulation of these
cells in vivo is helper cell dependent, and, if so, whether or
not the activation of the helper cells is peptide dependent.
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